On January 4, 2024, C4 Therapeutics, Inc. closed the transaction. The company issued 5,567,928 shares at an issue price of $4.49 per share for the gross proceeds of $24,999,996.72.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6 USD | -2.76% | -11.63% | +6.19% |
May. 09 | Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating | MT |
May. 08 | C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
41.65 CNY | -2.02% | -5.23% | 2.41B | ||
6 USD | -2.76% | -11.63% | 413M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.19% | 413M | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+49.67% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- CCCC Stock
- News C4 Therapeutics, Inc.
- C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.